Prescribing information


REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system1,2

REVOLADE is a once-daily film-coated tablet (FCT) for the treatment of patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatment (e.g. cortciosteroids, immunoglobulins).1


What can REVOLADE offer your ITP patients?

a target

Platelet control without immunosuppression1,2

Learn more

a tick list

Across 5 clinical trials3–7
In over 5000 global subjects8*

Learn more

a shield with a large tick inside it

10 years of real-world
clinical practice1

Learn more


Choose REVOLADE for your ITP patients with confidence1–8

FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.8
  1. REVOLADE Summary of Product Characteristics.
  2. Kuter D. Int J Hematol. 2013;98:10–23.
  3. Wong R, et al. Blood. 2017;130:2527–2536.
  4. Cheng G, et al. Lancet. 2011;377:393–402.
  5. Bussel J, et al. Br J Haematol. 2013;160:538–546.
  6. Bussel J, et al. Lancet. 2015;2:315–325.
  7. Grainger J, et al. Lancet. 2015;386:1649–1658.
IE | May 2022 | 174745

Click here for Product Information


Ask Speakers


Medical Information Request

Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: Adverse events could also be reported to Novartis preferably via or by email:[email protected] or by calling 01 2080 612.